Oncology News

Rucaparib monotherapy significantly extended PFS compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to topline data from the randomized phase 3 ATHENA-MONO trial.

Minimally invasive surgery conferred lower survival rates than open surgery among women with cervical cancer, according to randomized phase 3 trial results presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer.

Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results.

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

Black women undergoing treatment for gynecologic cancer reported significantly higher levels of race-associated stress compared with white women, according to study results.

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Women diagnosed with breast or gynecologic cancers underutilized both assisted reproductive technology and fertility-sparing oncology care, according to study results.

Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Adjuvant olaparib significantly extended OS among patients with HER2-negative high-risk early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the randomized phase 3 OlympiA study.

Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors in 75% of patients with recurrent or persistent estrogen receptor-positive, or ER-positive, endometrial cancer.